QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=A4ACC10A4D03A9D51305A2DDE4B1C225;jsessionid=010CEF7D9D46F8FF99B3EFFD4412ED44;jsessionid=83455787AA8EDC043E3CB42D24F9CE5E;jsessionid=1FD43B9A8139DF51ECE9451C98B4545C;jsessionid=19DF6D9A6AE96DB55D1D7914CAFCAC0E (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=A4ACC10A4D03A9D51305A2DDE4B1C225;jsessionid=010CEF7D9D46F8FF99B3EFFD4412ED44;jsessionid=83455787AA8EDC043E3CB42D24F9CE5E;jsessionid=1FD43B9A8139DF51ECE9451C98B4545C;jsessionid=19DF6D9A6AE96DB55D1D7914CAFCAC0E